Based on FIBCD1’s ability to dampen inflammatory responses in mucosal tissues, we hypothesized that enhanced FIBCD1 expression would lead to decreased intestinal inflammation and reduce the development of colitis-associated colon cancer. Here, FIBCD1 is linked to colitis.